Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: Predictors of efficacy and outcome

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 12, 2014, Pages 1398-1407

  Frivolt, K ^a,b   Schwerd, T ^a   Werkstetter, K J ^a   Schwarzer, A ^a   Schatz, S B ^a   Bufler, P ^a   Koletzko, S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; ENTERIC FEEDING; ERYTHROCYTE SEDIMENTATION RATE; EXCLUSIVE ENTERAL NUTRITION; FECES LEVEL; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; REPEAT PROCEDURE; RETROSPECTIVE STUDY; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901301002     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12770     Document Type: Article

References (28)

1. Van Assche G, Dignass A, Reinisch W, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
2. de Bie CI, Paerregaard A, Kolacek S, et al,. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 2013; 19: 378-85.
3. Werkstetter KJ, Pozza SB, Filipiak-Pittroff B, et al,. Long-term development of bone geometry and muscle in pediatric inflammatory bowel disease. Am J Gastroenterol 2011; 106: 988-98.
4. Heuschkel RB, Menache CC, Megerian JT, Baird AE,. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 8-15.
5. Fell JM, Paintin M, Arnaud-Battandier F, et al,. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-9.
6. Berni Canani R, Terrin G, Borrelli O, et al,. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006; 38: 381-7.
7. Day AS, Whitten KE, Lemberg DA, et al,. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006; 21: 1609-14.
8. Werkstetter KJ, Schatz SB, Alberer M, Filipiak-Pittroff B, Koletzko S,. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn's disease patients. Ann Nutr Metab 2013; 63: 10-6.
9. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
10. Levine A, Griffiths A, Markowitz J, et al,. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
11. Cho JH, Brant SR,. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-12.
12. Turner D, Griffiths AM, Walters TD, et al,. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012; 18: 55-62.
13. Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK,. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther 2009; 30: 501-7.
14. Knight C, El-Matary W, Spray C, Sandhu BK,. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005; 24: 775-9.
15. Rubio A, Pigneur B, Garnier-Lengline H, et al,. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther 2011; 33: 1332-9.
16. Afzal NA, Davies S, Paintin M, et al,. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005; 50: 1471-5.
17. Cameron FL, Gerasimidis K, Papangelou A, et al,. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2013; 37: 622-9.
18. Lambert B, Lemberg DA, Leach ST, Day AS,. Longer-term outcomes of nutritional management of Crohn's disease in children. Dig Dis Sci 2012; 57: 2171-7.
19. de Bie C, Kindermann A, Escher J,. Use of exclusive enteral nutrition in paediatric Crohn's disease in The Netherlands. J Crohns Colitis 2013; 7: 263-70.
20. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
21. Riello L, Talbotec C, Garnier-Lengline H, et al,. Tolerance and efficacy of azathioprine in pediatric Crohn's disease. Inflamm Bowel Dis 2011; 17: 2138-43.
22. Panes J, Lopez-Sanroman A, Bermejo F, et al,. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145: 766-74.e1.
23. Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P,. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011; 45: 234-9.
24. Russell RK, Drummond HE, Nimmo EE, et al,. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005; 11: 955-64.
25. Lacher M, Helmbrecht J, Schroepf S, et al,. NOD2 mutations predict the risk for surgery in pediatric-onset Crohn's disease. J Pediatr Surg 2010; 45: 1591-7.
26. Posovszky C, Pfalzer V, Lahr G, et al,. Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease. BMC Gastroenterol 2013; 13: 77.
27. de Ridder L, Weersma RK, Dijkstra G, et al,. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis 2007; 13: 1083-92.
28. Ferraris A, Knafelz D, Torres B, Fortina P, Castro M, Dallapiccola B,. Analysis of CARD15 gene variants in Italian pediatric patients with inflammatory bowel diseases. J Pediatr 2005; 147: 272-3.